The plant will manufacture Ellipta products.
GlaxoSmithKline’s (GSK’s) portfolio of respiratory Ellipta products, including Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), is experiencing strong increases in demand (approximately 20% in the second quarter of 2018). To meet the demand, the company has added a new manufacturing facility at its site in Montrose, Scotland, which opened in October 2018.
The $69 million addition will produce the active ingredients used in GSK Ellipta inhalers. The other plant producing these products is located in Singapore. Other products in the portfolio include Anoro (umeclidinium/vilanterol), Incruse (umeclidinium), Breo/Relvar (fluticasone furoate/vilanterol) and Arnuity (fluticasone). As with Trelegy, they are delivered using the Ellipta dry powder inhaler.
The company established a second site for production of its respiratory active pharmaceutical ingredients to ensure a stable global supply to meet growing demand.